Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| LENZ Therapeutics, Inc.GRPH · Entity 6475 | Director | July 19, 2023 | July 21, 2023 |
| Repare Therapeutics Inc.RPTX · Entity 68433 | Director | December 29, 2022 | January 03, 2023 |
| Turnstone Biologics Corp.TSBX · Entity 76646 | Director | August 08, 2025 | August 08, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
LENZ Therapeutics, Inc.
Report date July 19, 2023 · Filed July 21, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.72 · Expires 2033-07-18 | Direct | 20,000 |
Reported balance
After 2023-07-19 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-07-19 · Grant · Acquired 20,000 · Balance 20,000 F1: The shares subject to such option vest in full on the earlier of (i) the one-year anniversary of the grant date or on (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service as a director as of the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to such option vest in full on the earlier of (i) the one-year anniversary of the grant date or on (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service as a director as of the applicable vesting date.
Repare Therapeutics Inc.
Report date December 29, 2022 · Filed January 03, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | IndirectSee Footnote | 563,403 |
Reported balance
After 2022-12-29 transaction · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · 2022-12-29 · Other · Disposed 287,157 · Balance 563,403 F1: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Venture Capital V, L.P. ("VVC V") to its partners. F2: Shares held by VVC V. Versant Ventures V, LLC ("VV V") is the sole general partner of VVC V. The Reporting Person, a member of the Issuer's board of directors, is a managing director of VV V and may be deemed to share voting and dispositive power over the shares held by VVC V. Each of VV V and the Reporting Person disclaims beneficial ownership of the shares held by VVC V, except to the extent of their respective pecuniary interests therein. |
| Common SharesSEC Table I · non-derivative | IndirectSee Footnote | 62,026 |
Reported balance
After 2022-12-29 transaction · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · 2022-12-29 · Other · Acquired 62,026 · Balance 62,026 F3: Represents a change in the form of ownership of VV V by virtue of the receipt of shares in the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VVC V. F4: Shares held by VV V. The Reporting Person, a member of the Issuer's board of directors, is a managing director of VV V and may be deemed to share voting and dispositive power over the shares held by VV V; however, the Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein. |
| Common SharesSEC Table I · non-derivative | IndirectSee Footnote | 16,949 |
Reported balance
After 2022-12-29 transaction · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · 2022-12-29 · Other · Disposed 8,638 · Balance 16,949 F5: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Affiliates Fund V, L.P. ("VAF V") to its partners. F6: Shares held by VAF V. VV V is the sole general partner of VAF V. The Reporting Person, a member of the Issuer's board of directors, is a managing director of VV V and may be deemed to share voting and dispositive power over the shares held by VAF V. Each of VV V and the Reporting Person disclaims beneficial ownership of the shares held by VAF V, except to the extent of their respective pecuniary interests therein. |
| Common SharesSEC Table I · non-derivative | IndirectSee Footnote | 63,892 |
Reported balance
After 2022-12-29 transaction · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · 2022-12-29 · Other · Acquired 1,866 · Balance 63,892 F7: Represents a change in the form of ownership of VV V by virtue of the receipt of shares in the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VAF V. F4: Shares held by VV V. The Reporting Person, a member of the Issuer's board of directors, is a managing director of VV V and may be deemed to share voting and dispositive power over the shares held by VV V; however, the Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein. |
| Common SharesSEC Table I · non-derivative | IndirectSee Footnote | 18,761 |
Reported balance
After 2022-12-29 transaction · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · 2022-12-29 · Other · Disposed 9,561 · Balance 18,761 F8: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Ophthalmic Affiliates Fund I, L.P. ("VOAF I") to its partners. F9: Shares held by VOAF I. VV V is the sole general partner of VOAF I. The Reporting Person, a member of the Issuer's board of directors, is a managing director of VV V and may be deemed to share voting and dispositive power over the shares held by VOAF I. Each of VV V and the Reporting Person disclaims beneficial ownership of the shares held by VOAF I, except to the extent of their respective pecuniary interests therein. |
| Common SharesSEC Table I · non-derivative | IndirectSee Footnote | 65,957 |
Reported balance
After 2022-12-29 transaction · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · 2022-12-29 · Other · Acquired 2,065 · Balance 65,957 F10: Represents a change in the form of ownership of VV V by virtue of the receipt of shares in the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VOAF I. F4: Shares held by VV V. The Reporting Person, a member of the Issuer's board of directors, is a managing director of VV V and may be deemed to share voting and dispositive power over the shares held by VV V; however, the Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein. |
| Common SharesSEC Table I · non-derivative | IndirectSee Footnote | 0 |
Reported balance
After 2022-12-29 transaction · row 7
Holding and transaction disclosures are not merged.
1 source rowRow 7 · 2022-12-29 · Other · Disposed 65,957 · Balance 0 F11: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by VV V, to its members. F4: Shares held by VV V. The Reporting Person, a member of the Issuer's board of directors, is a managing director of VV V and may be deemed to share voting and dispositive power over the shares held by VV V; however, the Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein. |
| Common SharesSEC Table I · non-derivative | IndirectSee Footnote | 42,877 |
Reported balance
After 2022-12-29 transaction · row 9
Holding and transaction disclosures are not merged.
1 source rowRow 9 · 2022-12-29 · Other · Disposed 21,854 · Balance 42,877 F13: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Venture Capital V (Canada) LP ("VVC V (Canada)") to its partners. F14: Shares held by VVC V (Canada). Versant Ventures V (Canada) GP-GP, Inc. ("VV V (Canada) GP") is the sole general partner of Versant Ventures V (Canada), L.P. ("VV V (Canada)") and VV V (Canada) is the sole general partner of VVC V (Canada). The Reporting Person, a member of the Issuer's board of directors, is a director of VV V (Canada) GP and may be deemed to share voting and dispositive power over the shares held by VVC V (Canada). Each of VV V (Canada), VV V (Canada) GP and the Reporting Person disclaims beneficial ownership of the shares held by VVC V (Canada), except to the extent of their respective pecuniary interests therein. |
| Common SharesSEC Table I · non-derivative | IndirectSee Footnote | 4,721 |
Reported balance
After 2022-12-29 transaction · row 10
Holding and transaction disclosures are not merged.
1 source rowRow 10 · 2022-12-29 · Other · Acquired 4,721 · Balance 4,721 F15: Represents a change in the form of ownership of VV V (Canada) by virtue of the receipt of shares in the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VVC V (Canada). F16: Shares held by VV V (Canada). VV V (Canada) GP is the sole general partner of VV V (Canada). The Reporting Person, a member of the Issuer's board of directors, is a director of VV V (Canada) GP and may be deemed to share voting and dispositive power over the shares held by VV V (Canada). Each of VV V (Canada) GP and the Reporting Person disclaims beneficial ownership of the shares held by VV V (Canada), except to the extent of their respective pecuniary interests therein. |
| Common SharesSEC Table I · non-derivative | IndirectSee Footnote | 0 |
Reported balance
After 2022-12-29 transaction · row 11
Holding and transaction disclosures are not merged.
1 source rowRow 11 · 2022-12-29 · Other · Disposed 4,721 · Balance 0 F17: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by VV V (Canada), to its partners. F16: Shares held by VV V (Canada). VV V (Canada) GP is the sole general partner of VV V (Canada). The Reporting Person, a member of the Issuer's board of directors, is a director of VV V (Canada) GP and may be deemed to share voting and dispositive power over the shares held by VV V (Canada). Each of VV V (Canada) GP and the Reporting Person disclaims beneficial ownership of the shares held by VV V (Canada), except to the extent of their respective pecuniary interests therein. |
| Common SharesSEC Table I · non-derivative | IndirectSee Footnote | 2,094,451 |
Reported balance
Holding disclosure · report date 2022-12-29 · row 13
Holding and transaction disclosures are not merged.
1 source rowRow 13 · Balance 2,094,451 F19: Shares held by Versant Venture Capital VI, L.P. ("VVC VI"). Versant Ventures VI GP-GP, LLC ("VV VI GP") is the sole general partner of Versant Ventures VI GP, L.P. ("VV VI") and VV VI is the sole general partner of VVC VI. The Reporting Person, a member of the Issuer's board of directors, is a managing director of VV VI GP and may be deemed to share voting and dispositive power over the shares held by VVC VI. Each of VV VI GP, VV VI and the Reporting Person disclaims beneficial ownership of the shares held by VVC VI, except to the extent of their respective pecuniary interests therein. |
| Common SharesSEC Table I · non-derivative | IndirectSee Footnote | 231,211 |
Reported balance
Holding disclosure · report date 2022-12-29 · row 14
Holding and transaction disclosures are not merged.
1 source rowRow 14 · Balance 231,211 F20: Shares held by Versant Vantage I, L.P. ("VV I"). Versant Vantage I GP-GP, LLC ("VV I GP-GP") is the sole general partner of Versant Vantage I GP, L.P. ("VV I GP") and VV I GP is the sole general partner of VV I. The Reporting Person, a member of the Issuer's board of directors, is a managing director of VV I GP-GP and may be deemed to share voting and dispositive power over the shares held by VV I. Each of VV I GP-GP, VV I GP and the Reporting Person disclaims beneficial ownership of the shares held by VV I, except to the extent of their respective pecuniary interests therein. |
| Common SharesSEC Table I · non-derivative | Direct | 25,131 |
Ending reported balance
After 2022-12-29 transaction · row 12
2 source rows · reconciled sequenceRow 8 · 2022-12-29 · Other · Acquired 1,240 · Balance 22,117 F12: Represents a change in the form of ownership of the Reporting Person by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VV V. Row 12 · 2022-12-29 · Other · Acquired 3,014 · Balance 25,131 F18: Represents a change in the form of ownership of the Reporting Person by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VV V (Canada). |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Venture Capital V, L.P. ("VVC V") to its partners.
F2: Shares held by VVC V. Versant Ventures V, LLC ("VV V") is the sole general partner of VVC V. The Reporting Person, a member of the Issuer's board of directors, is a managing director of VV V and may be deemed to share voting and dispositive power over the shares held by VVC V. Each of VV V and the Reporting Person disclaims beneficial ownership of the shares held by VVC V, except to the extent of their respective pecuniary interests therein.
F3: Represents a change in the form of ownership of VV V by virtue of the receipt of shares in the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VVC V.
F4: Shares held by VV V. The Reporting Person, a member of the Issuer's board of directors, is a managing director of VV V and may be deemed to share voting and dispositive power over the shares held by VV V; however, the Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein.
F5: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Affiliates Fund V, L.P. ("VAF V") to its partners.
F6: Shares held by VAF V. VV V is the sole general partner of VAF V. The Reporting Person, a member of the Issuer's board of directors, is a managing director of VV V and may be deemed to share voting and dispositive power over the shares held by VAF V. Each of VV V and the Reporting Person disclaims beneficial ownership of the shares held by VAF V, except to the extent of their respective pecuniary interests therein.
F7: Represents a change in the form of ownership of VV V by virtue of the receipt of shares in the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VAF V.
F8: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Ophthalmic Affiliates Fund I, L.P. ("VOAF I") to its partners.
F9: Shares held by VOAF I. VV V is the sole general partner of VOAF I. The Reporting Person, a member of the Issuer's board of directors, is a managing director of VV V and may be deemed to share voting and dispositive power over the shares held by VOAF I. Each of VV V and the Reporting Person disclaims beneficial ownership of the shares held by VOAF I, except to the extent of their respective pecuniary interests therein.
F10: Represents a change in the form of ownership of VV V by virtue of the receipt of shares in the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VOAF I.
F11: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by VV V, to its members.
F12: Represents a change in the form of ownership of the Reporting Person by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VV V.
F13: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Venture Capital V (Canada) LP ("VVC V (Canada)") to its partners.
F14: Shares held by VVC V (Canada). Versant Ventures V (Canada) GP-GP, Inc. ("VV V (Canada) GP") is the sole general partner of Versant Ventures V (Canada), L.P. ("VV V (Canada)") and VV V (Canada) is the sole general partner of VVC V (Canada). The Reporting Person, a member of the Issuer's board of directors, is a director of VV V (Canada) GP and may be deemed to share voting and dispositive power over the shares held by VVC V (Canada). Each of VV V (Canada), VV V (Canada) GP and the Reporting Person disclaims beneficial ownership of the shares held by VVC V (Canada), except to the extent of their respective pecuniary interests therein.
F15: Represents a change in the form of ownership of VV V (Canada) by virtue of the receipt of shares in the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VVC V (Canada).
F16: Shares held by VV V (Canada). VV V (Canada) GP is the sole general partner of VV V (Canada). The Reporting Person, a member of the Issuer's board of directors, is a director of VV V (Canada) GP and may be deemed to share voting and dispositive power over the shares held by VV V (Canada). Each of VV V (Canada) GP and the Reporting Person disclaims beneficial ownership of the shares held by VV V (Canada), except to the extent of their respective pecuniary interests therein.
F17: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by VV V (Canada), to its partners.
F18: Represents a change in the form of ownership of the Reporting Person by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VV V (Canada).
F19: Shares held by Versant Venture Capital VI, L.P. ("VVC VI"). Versant Ventures VI GP-GP, LLC ("VV VI GP") is the sole general partner of Versant Ventures VI GP, L.P. ("VV VI") and VV VI is the sole general partner of VVC VI. The Reporting Person, a member of the Issuer's board of directors, is a managing director of VV VI GP and may be deemed to share voting and dispositive power over the shares held by VVC VI. Each of VV VI GP, VV VI and the Reporting Person disclaims beneficial ownership of the shares held by VVC VI, except to the extent of their respective pecuniary interests therein.
F20: Shares held by Versant Vantage I, L.P. ("VV I"). Versant Vantage I GP-GP, LLC ("VV I GP-GP") is the sole general partner of Versant Vantage I GP, L.P. ("VV I GP") and VV I GP is the sole general partner of VV I. The Reporting Person, a member of the Issuer's board of directors, is a managing director of VV I GP-GP and may be deemed to share voting and dispositive power over the shares held by VV I. Each of VV I GP-GP, VV I GP and the Reporting Person disclaims beneficial ownership of the shares held by VV I, except to the extent of their respective pecuniary interests therein.
Turnstone Biologics Corp.
Report date August 08, 2025 · Filed August 08, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Versant Vantage II, L.P. | 0 |
Reported balance
After 2025-08-08 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2025-08-08 · Other · Disposed 274,990 · Balance 0 F1: Disposed of pursuant to the terms of the Agreement and Plan of Merger, dated June 26, 2025, by and among the Issuer, XOMA Royalty Corporation ("Purchaser") and XRA 3 Corp., a wholly-owned subsidiary of Purchaser, pursuant to which Purchaser completed a cash tender offer for all outstanding shares of common stock of the Issuer for (i) $0.34 per share in cash, payable subject to any applicable tax withholding and without interest, plus (ii) one non-transferable contractual contingent value right per share, payable subject to any applicable tax withholding and without interest. F2: Shares held by Versant Vantage II, L.P. ("Vantage II"). Versant Vantage II GP, L.P. ("Vantage II GP") is the sole general partner of Vantage II and Versant Vantage II GP-GP, LLC (Vantage II GP-GP") is the sole general partner of Vantage II GP. The Reporting Person, a member of the Issuer's board of directors, is a managing director of Vantage II GP-GP and may be deemed to share voting and dispositive power over the shares held by Vantage II. The Reporting Person disclaims beneficial ownership of the shares held by Canada V, except to the extent of his respective pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Versant Venture Capital V, L.P. | 0 |
Reported balance
After 2025-08-08 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2025-08-08 · Other · Disposed 2,726,322 · Balance 0 F1: Disposed of pursuant to the terms of the Agreement and Plan of Merger, dated June 26, 2025, by and among the Issuer, XOMA Royalty Corporation ("Purchaser") and XRA 3 Corp., a wholly-owned subsidiary of Purchaser, pursuant to which Purchaser completed a cash tender offer for all outstanding shares of common stock of the Issuer for (i) $0.34 per share in cash, payable subject to any applicable tax withholding and without interest, plus (ii) one non-transferable contractual contingent value right per share, payable subject to any applicable tax withholding and without interest. F3: Shares are held by Versant Venture Capital V, L.P. ("Versant V"). Versant Ventures V, LLC ("Versant V GP") is the sole general partner of Versant V. The Reporting Person, a member of the Issuer's board of directors, is a managing director of Versant V GP and may be deemed to share voting and dispositive power over the shares held by Versant V. The Reporting Persons disclaims beneficial ownership of the shares held by Versant V, except to the extent of his respective pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Versant Venture Capital V (Canada) LP | 0 |
Reported balance
After 2025-08-08 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2025-08-08 · Other · Disposed 207,486 · Balance 0 F1: Disposed of pursuant to the terms of the Agreement and Plan of Merger, dated June 26, 2025, by and among the Issuer, XOMA Royalty Corporation ("Purchaser") and XRA 3 Corp., a wholly-owned subsidiary of Purchaser, pursuant to which Purchaser completed a cash tender offer for all outstanding shares of common stock of the Issuer for (i) $0.34 per share in cash, payable subject to any applicable tax withholding and without interest, plus (ii) one non-transferable contractual contingent value right per share, payable subject to any applicable tax withholding and without interest. F4: Shares are held by Versant Venture Capital V (Canada) LP ("Canada V"). Versant Ventures V (Canada), L.P. ("Canada V GP") is the general partner of Canada V and Versant Ventures V GP-GP (Canada), Inc. ("Canada V GP-GP") is the sole general partner of Canada V GP. The Reporting Person, a member of the Issuer's board of directors, is a director of Canada V GP-GP and may be deemed to share voting and dispositive power over the shares held by Canada V. The Reporting Person disclaims beneficial ownership of the shares held by Canada V, except to the extent of his respective pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Versant Ophthalmic Affiliates Fund I, L.P. | 0 |
Reported balance
After 2025-08-08 transaction · row 4
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 4 · 2025-08-08 · Other · Disposed 90,888 · Balance 0 F1: Disposed of pursuant to the terms of the Agreement and Plan of Merger, dated June 26, 2025, by and among the Issuer, XOMA Royalty Corporation ("Purchaser") and XRA 3 Corp., a wholly-owned subsidiary of Purchaser, pursuant to which Purchaser completed a cash tender offer for all outstanding shares of common stock of the Issuer for (i) $0.34 per share in cash, payable subject to any applicable tax withholding and without interest, plus (ii) one non-transferable contractual contingent value right per share, payable subject to any applicable tax withholding and without interest. F5: Shares are held by Versant Ophthalmic Affiliates Fund I, L.P. ("Ophthalmic"). Versant V GP is the sole general partner of Ophthalmic. The Reporting Person, a member of the Issuer's board of directors, is a managing director of Versant V GP and may be deemed to share voting and dispositive power over the shares held by Ophthalmic. The Reporting Person disclaims beneficial ownership of the shares held by Ophthalmic, except to the extent of his respective pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Versant Affiliates Fund V, L.P. | 0 |
Reported balance
After 2025-08-08 transaction · row 5
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 5 · 2025-08-08 · Other · Disposed 82,006 · Balance 0 F1: Disposed of pursuant to the terms of the Agreement and Plan of Merger, dated June 26, 2025, by and among the Issuer, XOMA Royalty Corporation ("Purchaser") and XRA 3 Corp., a wholly-owned subsidiary of Purchaser, pursuant to which Purchaser completed a cash tender offer for all outstanding shares of common stock of the Issuer for (i) $0.34 per share in cash, payable subject to any applicable tax withholding and without interest, plus (ii) one non-transferable contractual contingent value right per share, payable subject to any applicable tax withholding and without interest. F6: Shares are held by Versant Affiliates Fund V, L.P. ("Affiliates V"). Versant V GP is the sole general partner of Affiliates V. The Reporting Person, a member of the Issuer's board of directors, is a managing director of Versant V GP and may be deemed to share voting and dispositive power over the shares held by Affiliates V. The Reporting Person disclaims beneficial ownership of the shares held by Affiliates, except to the extent of his respective pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to the terms of the Agreement and Plan of Merger, dated June 26, 2025, by and among the Issuer, XOMA Royalty Corporation ("Purchaser") and XRA 3 Corp., a wholly-owned subsidiary of Purchaser, pursuant to which Purchaser completed a cash tender offer for all outstanding shares of common stock of the Issuer for (i) $0.34 per share in cash, payable subject to any applicable tax withholding and without interest, plus (ii) one non-transferable contractual contingent value right per share, payable subject to any applicable tax withholding and without interest.
F2: Shares held by Versant Vantage II, L.P. ("Vantage II"). Versant Vantage II GP, L.P. ("Vantage II GP") is the sole general partner of Vantage II and Versant Vantage II GP-GP, LLC (Vantage II GP-GP") is the sole general partner of Vantage II GP. The Reporting Person, a member of the Issuer's board of directors, is a managing director of Vantage II GP-GP and may be deemed to share voting and dispositive power over the shares held by Vantage II. The Reporting Person disclaims beneficial ownership of the shares held by Canada V, except to the extent of his respective pecuniary interest therein.
F3: Shares are held by Versant Venture Capital V, L.P. ("Versant V"). Versant Ventures V, LLC ("Versant V GP") is the sole general partner of Versant V. The Reporting Person, a member of the Issuer's board of directors, is a managing director of Versant V GP and may be deemed to share voting and dispositive power over the shares held by Versant V. The Reporting Persons disclaims beneficial ownership of the shares held by Versant V, except to the extent of his respective pecuniary interest therein.
F4: Shares are held by Versant Venture Capital V (Canada) LP ("Canada V"). Versant Ventures V (Canada), L.P. ("Canada V GP") is the general partner of Canada V and Versant Ventures V GP-GP (Canada), Inc. ("Canada V GP-GP") is the sole general partner of Canada V GP. The Reporting Person, a member of the Issuer's board of directors, is a director of Canada V GP-GP and may be deemed to share voting and dispositive power over the shares held by Canada V. The Reporting Person disclaims beneficial ownership of the shares held by Canada V, except to the extent of his respective pecuniary interest therein.
F5: Shares are held by Versant Ophthalmic Affiliates Fund I, L.P. ("Ophthalmic"). Versant V GP is the sole general partner of Ophthalmic. The Reporting Person, a member of the Issuer's board of directors, is a managing director of Versant V GP and may be deemed to share voting and dispositive power over the shares held by Ophthalmic. The Reporting Person disclaims beneficial ownership of the shares held by Ophthalmic, except to the extent of his respective pecuniary interest therein.
F6: Shares are held by Versant Affiliates Fund V, L.P. ("Affiliates V"). Versant V GP is the sole general partner of Affiliates V. The Reporting Person, a member of the Issuer's board of directors, is a managing director of Versant V GP and may be deemed to share voting and dispositive power over the shares held by Affiliates V. The Reporting Person disclaims beneficial ownership of the shares held by Affiliates, except to the extent of his respective pecuniary interest therein.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
CHINOOK THERAPEUTICS, INC.
Report date August 11, 2023 · Filed August 11, 2023
Section 16 reporting ended · disclosed 2023-08-11. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-08-11 transaction · row 1
1 source rowRow 1 · 2023-08-11 · Disposition to issuer · Disposed 447,013 · Balance 0 F1: The reported securities were disposed of pursuant to the Merger Agreement (defined in the Remarks below). Upon effectiveness of the Merger (defined in the Remarks below), in exchange for each share of the Issuer's Common Stock, the reporting person received: (i) $40.00 in cash, without interest and less applicable withholding taxes; and (ii) one contractual contingent value right (each, a "CVR"), entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement (the "Contingent Value Rights Agreement") entered into concurrent with completion of the Merger. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 0 |
Reported balance
After 2023-08-11 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2023-08-11 · Disposition to issuer · Disposed 2,105,107 · Balance 0 F1: The reported securities were disposed of pursuant to the Merger Agreement (defined in the Remarks below). Upon effectiveness of the Merger (defined in the Remarks below), in exchange for each share of the Issuer's Common Stock, the reporting person received: (i) $40.00 in cash, without interest and less applicable withholding taxes; and (ii) one contractual contingent value right (each, a "CVR"), entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement (the "Contingent Value Rights Agreement") entered into concurrent with completion of the Merger. F2: These securities are held of record by Versant Venture Capital VII, L.P. ("Versant VII"). Versant Ventures VII GP, L.P. ("Versant Ventures VII GP") is the general partner of Versant VII, and Versant Ventures VII GP-GP, LLC ("Versant Ventures VII GP-GP") is the general partner of Versant Ventures VII GP. Jerel C. Davis is a member of the Issuer's board of directors and is a managing director of Versant Ventures VII GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant VII. Each of Jerel C. Davis, Versant Ventures VII GP-GP, and Versant Ventures VII GP disclaims beneficial ownership of the shares held by Versant VII, except to the extent of their respective pecuniary interests therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 0 |
Reported balance
After 2023-08-11 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2023-08-11 · Disposition to issuer · Disposed 719,104 · Balance 0 F1: The reported securities were disposed of pursuant to the Merger Agreement (defined in the Remarks below). Upon effectiveness of the Merger (defined in the Remarks below), in exchange for each share of the Issuer's Common Stock, the reporting person received: (i) $40.00 in cash, without interest and less applicable withholding taxes; and (ii) one contractual contingent value right (each, a "CVR"), entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement (the "Contingent Value Rights Agreement") entered into concurrent with completion of the Merger. F3: These securities are held of record by Versant Voyageurs I, L.P. ("Versant Voyageurs I"). Versant Voyageurs I GP Company is the general partner of Versant Voyageurs I. Jerel C. Davis is a member of the Issuer's board of directors and is a director of Versant Voyageurs I GP Company and may be deemed to share voting and dispositive power over the shares held by Versant Voyageurs I. Each of Jerel C. Davis and Versant Voyageurs I GP Company disclaims beneficial ownership of the shares held by Versant Voyageurs I, except to the extent of their respective pecuniary interests therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 0 |
Reported balance
After 2023-08-11 transaction · row 4
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 4 · 2023-08-11 · Disposition to issuer · Disposed 210,996 · Balance 0 F1: The reported securities were disposed of pursuant to the Merger Agreement (defined in the Remarks below). Upon effectiveness of the Merger (defined in the Remarks below), in exchange for each share of the Issuer's Common Stock, the reporting person received: (i) $40.00 in cash, without interest and less applicable withholding taxes; and (ii) one contractual contingent value right (each, a "CVR"), entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement (the "Contingent Value Rights Agreement") entered into concurrent with completion of the Merger. F4: These securities are held of record by Versant Voyageurs I Parallel, L.P. ("Versant I Parallel"). Versant Voyageurs I GP, L.P. ("Versant Voyageurs I GP") is the general partner of Versant I Parallel. Versant Ventures VI GP, L.P. ("Versant Ventures VI GP") is the general partner of Versant Voyageurs I GP. Versant Ventures VI GP-GP, LLC ("Versant Ventures VI GP-GP") is the general partner of Versant Ventures VI GP. Jerel C. Davis is a member of the Issuer's board of directors and is a managing director of Versant Ventures VI GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant I Parallel. Each of Jerel C. Davis, Versant Ventures VI GP-GP, Versant Ventures VI GP, and Versant Voyageurs I GP disclaims beneficial ownership of the shares held by Versant I Parallel, except to the extent of their respective pecuniary interests therein. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.77 · Expires 2030-10-05 | Direct | 0 |
Reported balance
After 2023-08-11 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-08-11 · Disposition to issuer · Disposed 23,522 · Balance 0 F5: This stock option award, which provided for ratable vesting in 36 monthly installments beginning on November 6, 2020, became fully vested and was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.81 · Expires 2031-06-03 | Direct | 0 |
Reported balance
After 2023-08-11 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2023-08-11 · Disposition to issuer · Disposed 5,948 · Balance 0 F6: This stock option award, which vested in full upon the earlier of the one year anniversary of the grant date or the date of the Issuer's next annual stockholders' meeting, was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.88 · Expires 2032-05-25 | Direct | 0 |
Reported balance
After 2023-08-11 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2023-08-11 · Disposition to issuer · Disposed 13,300 · Balance 0 F6: This stock option award, which vested in full upon the earlier of the one year anniversary of the grant date or the date of the Issuer's next annual stockholders' meeting, was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported securities were disposed of pursuant to the Merger Agreement (defined in the Remarks below). Upon effectiveness of the Merger (defined in the Remarks below), in exchange for each share of the Issuer's Common Stock, the reporting person received: (i) $40.00 in cash, without interest and less applicable withholding taxes; and (ii) one contractual contingent value right (each, a "CVR"), entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement (the "Contingent Value Rights Agreement") entered into concurrent with completion of the Merger.
F2: These securities are held of record by Versant Venture Capital VII, L.P. ("Versant VII"). Versant Ventures VII GP, L.P. ("Versant Ventures VII GP") is the general partner of Versant VII, and Versant Ventures VII GP-GP, LLC ("Versant Ventures VII GP-GP") is the general partner of Versant Ventures VII GP. Jerel C. Davis is a member of the Issuer's board of directors and is a managing director of Versant Ventures VII GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant VII. Each of Jerel C. Davis, Versant Ventures VII GP-GP, and Versant Ventures VII GP disclaims beneficial ownership of the shares held by Versant VII, except to the extent of their respective pecuniary interests therein.
F3: These securities are held of record by Versant Voyageurs I, L.P. ("Versant Voyageurs I"). Versant Voyageurs I GP Company is the general partner of Versant Voyageurs I. Jerel C. Davis is a member of the Issuer's board of directors and is a director of Versant Voyageurs I GP Company and may be deemed to share voting and dispositive power over the shares held by Versant Voyageurs I. Each of Jerel C. Davis and Versant Voyageurs I GP Company disclaims beneficial ownership of the shares held by Versant Voyageurs I, except to the extent of their respective pecuniary interests therein.
F4: These securities are held of record by Versant Voyageurs I Parallel, L.P. ("Versant I Parallel"). Versant Voyageurs I GP, L.P. ("Versant Voyageurs I GP") is the general partner of Versant I Parallel. Versant Ventures VI GP, L.P. ("Versant Ventures VI GP") is the general partner of Versant Voyageurs I GP. Versant Ventures VI GP-GP, LLC ("Versant Ventures VI GP-GP") is the general partner of Versant Ventures VI GP. Jerel C. Davis is a member of the Issuer's board of directors and is a managing director of Versant Ventures VI GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant I Parallel. Each of Jerel C. Davis, Versant Ventures VI GP-GP, Versant Ventures VI GP, and Versant Voyageurs I GP disclaims beneficial ownership of the shares held by Versant I Parallel, except to the extent of their respective pecuniary interests therein.
F5: This stock option award, which provided for ratable vesting in 36 monthly installments beginning on November 6, 2020, became fully vested and was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes.
F6: This stock option award, which vested in full upon the earlier of the one year anniversary of the grant date or the date of the Issuer's next annual stockholders' meeting, was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 08, 2025 Filed Aug 8, 2025 16:06 UTC | Turnstone Biologics Corp. TSBX · Entity 76646 | OtherCommon Stock | 82,006 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-021338 · form4-08082025_080854.xml · nonDerivative · entry 5 Jerel Davis · CIK 0001745958 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Versant Affiliates Fund V, L.P. Disclosed balance after: 0 F1 · kind: Disposed of pursuant to the terms of the Agreement and Plan of Merger, dated June 26, 2025, by and among the Issuer, XOMA Royalty Corporation ("Purchaser") and XRA 3 Corp., a wholly-owned subsidiary of Purchaser, pursuant to which Purchaser completed a cash tender offer for all outstanding shares of common stock of the Issuer for (i) $0.34 per share in cash, payable subject to any applicable tax withholding and without interest, plus (ii) one non-transferable contractual contingent value right per share, payable subject to any applicable tax withholding and without interest. F1 · price: Disposed of pursuant to the terms of the Agreement and Plan of Merger, dated June 26, 2025, by and among the Issuer, XOMA Royalty Corporation ("Purchaser") and XRA 3 Corp., a wholly-owned subsidiary of Purchaser, pursuant to which Purchaser completed a cash tender offer for all outstanding shares of common stock of the Issuer for (i) $0.34 per share in cash, payable subject to any applicable tax withholding and without interest, plus (ii) one non-transferable contractual contingent value right per share, payable subject to any applicable tax withholding and without interest. F6 · ownership.nature: Shares are held by Versant Affiliates Fund V, L.P. ("Affiliates V"). Versant V GP is the sole general partner of Affiliates V. The Reporting Person, a member of the Issuer's board of directors, is a managing director of Versant V GP and may be deemed to share voting and dispositive power over the shares held by Affiliates V. The Reporting Person disclaims beneficial ownership of the shares held by Affiliates, except to the extent of his respective pecuniary interest therein. Read SEC document |
| August 08, 2025 Filed Aug 8, 2025 16:06 UTC | Turnstone Biologics Corp. TSBX · Entity 76646 | OtherCommon Stock | 90,888 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-021338 · form4-08082025_080854.xml · nonDerivative · entry 4 Jerel Davis · CIK 0001745958 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Versant Ophthalmic Affiliates Fund I, L.P. Disclosed balance after: 0 F1 · kind: Disposed of pursuant to the terms of the Agreement and Plan of Merger, dated June 26, 2025, by and among the Issuer, XOMA Royalty Corporation ("Purchaser") and XRA 3 Corp., a wholly-owned subsidiary of Purchaser, pursuant to which Purchaser completed a cash tender offer for all outstanding shares of common stock of the Issuer for (i) $0.34 per share in cash, payable subject to any applicable tax withholding and without interest, plus (ii) one non-transferable contractual contingent value right per share, payable subject to any applicable tax withholding and without interest. F1 · price: Disposed of pursuant to the terms of the Agreement and Plan of Merger, dated June 26, 2025, by and among the Issuer, XOMA Royalty Corporation ("Purchaser") and XRA 3 Corp., a wholly-owned subsidiary of Purchaser, pursuant to which Purchaser completed a cash tender offer for all outstanding shares of common stock of the Issuer for (i) $0.34 per share in cash, payable subject to any applicable tax withholding and without interest, plus (ii) one non-transferable contractual contingent value right per share, payable subject to any applicable tax withholding and without interest. F5 · ownership.nature: Shares are held by Versant Ophthalmic Affiliates Fund I, L.P. ("Ophthalmic"). Versant V GP is the sole general partner of Ophthalmic. The Reporting Person, a member of the Issuer's board of directors, is a managing director of Versant V GP and may be deemed to share voting and dispositive power over the shares held by Ophthalmic. The Reporting Person disclaims beneficial ownership of the shares held by Ophthalmic, except to the extent of his respective pecuniary interest therein. Read SEC document |
| August 08, 2025 Filed Aug 8, 2025 16:06 UTC | Turnstone Biologics Corp. TSBX · Entity 76646 | OtherCommon Stock | 207,486 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-021338 · form4-08082025_080854.xml · nonDerivative · entry 3 Jerel Davis · CIK 0001745958 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Versant Venture Capital V (Canada) LP Disclosed balance after: 0 F1 · kind: Disposed of pursuant to the terms of the Agreement and Plan of Merger, dated June 26, 2025, by and among the Issuer, XOMA Royalty Corporation ("Purchaser") and XRA 3 Corp., a wholly-owned subsidiary of Purchaser, pursuant to which Purchaser completed a cash tender offer for all outstanding shares of common stock of the Issuer for (i) $0.34 per share in cash, payable subject to any applicable tax withholding and without interest, plus (ii) one non-transferable contractual contingent value right per share, payable subject to any applicable tax withholding and without interest. F1 · price: Disposed of pursuant to the terms of the Agreement and Plan of Merger, dated June 26, 2025, by and among the Issuer, XOMA Royalty Corporation ("Purchaser") and XRA 3 Corp., a wholly-owned subsidiary of Purchaser, pursuant to which Purchaser completed a cash tender offer for all outstanding shares of common stock of the Issuer for (i) $0.34 per share in cash, payable subject to any applicable tax withholding and without interest, plus (ii) one non-transferable contractual contingent value right per share, payable subject to any applicable tax withholding and without interest. F4 · ownership.nature: Shares are held by Versant Venture Capital V (Canada) LP ("Canada V"). Versant Ventures V (Canada), L.P. ("Canada V GP") is the general partner of Canada V and Versant Ventures V GP-GP (Canada), Inc. ("Canada V GP-GP") is the sole general partner of Canada V GP. The Reporting Person, a member of the Issuer's board of directors, is a director of Canada V GP-GP and may be deemed to share voting and dispositive power over the shares held by Canada V. The Reporting Person disclaims beneficial ownership of the shares held by Canada V, except to the extent of his respective pecuniary interest therein. Read SEC document |
| August 08, 2025 Filed Aug 8, 2025 16:06 UTC | Turnstone Biologics Corp. TSBX · Entity 76646 | OtherCommon Stock | 2,726,322 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-021338 · form4-08082025_080854.xml · nonDerivative · entry 2 Jerel Davis · CIK 0001745958 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Versant Venture Capital V, L.P. Disclosed balance after: 0 F1 · kind: Disposed of pursuant to the terms of the Agreement and Plan of Merger, dated June 26, 2025, by and among the Issuer, XOMA Royalty Corporation ("Purchaser") and XRA 3 Corp., a wholly-owned subsidiary of Purchaser, pursuant to which Purchaser completed a cash tender offer for all outstanding shares of common stock of the Issuer for (i) $0.34 per share in cash, payable subject to any applicable tax withholding and without interest, plus (ii) one non-transferable contractual contingent value right per share, payable subject to any applicable tax withholding and without interest. F1 · price: Disposed of pursuant to the terms of the Agreement and Plan of Merger, dated June 26, 2025, by and among the Issuer, XOMA Royalty Corporation ("Purchaser") and XRA 3 Corp., a wholly-owned subsidiary of Purchaser, pursuant to which Purchaser completed a cash tender offer for all outstanding shares of common stock of the Issuer for (i) $0.34 per share in cash, payable subject to any applicable tax withholding and without interest, plus (ii) one non-transferable contractual contingent value right per share, payable subject to any applicable tax withholding and without interest. F3 · ownership.nature: Shares are held by Versant Venture Capital V, L.P. ("Versant V"). Versant Ventures V, LLC ("Versant V GP") is the sole general partner of Versant V. The Reporting Person, a member of the Issuer's board of directors, is a managing director of Versant V GP and may be deemed to share voting and dispositive power over the shares held by Versant V. The Reporting Persons disclaims beneficial ownership of the shares held by Versant V, except to the extent of his respective pecuniary interest therein. Read SEC document |
| August 08, 2025 Filed Aug 8, 2025 16:06 UTC | Turnstone Biologics Corp. TSBX · Entity 76646 | OtherCommon Stock | 274,990 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-021338 · form4-08082025_080854.xml · nonDerivative · entry 1 Jerel Davis · CIK 0001745958 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Versant Vantage II, L.P. Disclosed balance after: 0 F1 · kind: Disposed of pursuant to the terms of the Agreement and Plan of Merger, dated June 26, 2025, by and among the Issuer, XOMA Royalty Corporation ("Purchaser") and XRA 3 Corp., a wholly-owned subsidiary of Purchaser, pursuant to which Purchaser completed a cash tender offer for all outstanding shares of common stock of the Issuer for (i) $0.34 per share in cash, payable subject to any applicable tax withholding and without interest, plus (ii) one non-transferable contractual contingent value right per share, payable subject to any applicable tax withholding and without interest. F1 · price: Disposed of pursuant to the terms of the Agreement and Plan of Merger, dated June 26, 2025, by and among the Issuer, XOMA Royalty Corporation ("Purchaser") and XRA 3 Corp., a wholly-owned subsidiary of Purchaser, pursuant to which Purchaser completed a cash tender offer for all outstanding shares of common stock of the Issuer for (i) $0.34 per share in cash, payable subject to any applicable tax withholding and without interest, plus (ii) one non-transferable contractual contingent value right per share, payable subject to any applicable tax withholding and without interest. F2 · ownership.nature: Shares held by Versant Vantage II, L.P. ("Vantage II"). Versant Vantage II GP, L.P. ("Vantage II GP") is the sole general partner of Vantage II and Versant Vantage II GP-GP, LLC (Vantage II GP-GP") is the sole general partner of Vantage II GP. The Reporting Person, a member of the Issuer's board of directors, is a managing director of Vantage II GP-GP and may be deemed to share voting and dispositive power over the shares held by Vantage II. The Reporting Person disclaims beneficial ownership of the shares held by Canada V, except to the extent of his respective pecuniary interest therein. Read SEC document |
| June 03, 2024 Filed Jul 2, 2024 16:45 UTC | Turnstone Biologics Corp. TSBX · Entity 76646 | GrantStock Option (Right to Buy) · Derivative | 12,770 | $0.00 Strike: $2.69 | $0.00 |
DisclosureSEC source: 0001415889-24-018923 · form4-07022024_040704.xml · derivative · entry 1 Jerel Davis · CIK 0001745958 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,770 Underlying: Common Stock · 12,770 shares Expires 2034-06-02 F1 · derivative.exercise_date: The shares subject to the option will vest on the earlier of June 3, 2025 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date. Read SEC document |
| October 16, 2023 Filed Oct 17, 2023 18:39 UTC | Turnstone Biologics Corp. TSBX · Entity 76646 | GrantStock Option (Right to Buy) · Derivative | 25,540 | $0.00 Strike: $2.61 | $0.00 |
DisclosureSEC source: 0001209191-23-053002 · doc4.xml · derivative · entry 1 Jerel Davis · CIK 0001745958 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,540 Underlying: Common Stock · 25,540 shares Expires 2033-10-15 F1 · derivative.exercise_date: Thirty three and thirty three one hundreds percent (33.33%) (and thirty three and thirty four one hundreds percent (33.34%) for year three) of the shares subject to the option will vest in three (3) annual installments commencing on the date of the first annual general meeting of stockholders occurring after October 12, 2023, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| August 11, 2023 Filed Aug 11, 2023 16:06 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | Disposition to issuerStock Option (Right to Buy) · Derivative | 13,300 | $26.12 Strike: $13.88 | $347,396.00 |
DisclosureSEC source: 0001209191-23-045415 · doc4.xml · derivative · entry 7 Jerel Davis · CIK 0001745958 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,300 shares Expires 2032-05-25 F6 · derivative.exercise_date: This stock option award, which vested in full upon the earlier of the one year anniversary of the grant date or the date of the Issuer's next annual stockholders' meeting, was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes. Read SEC document |
| August 11, 2023 Filed Aug 11, 2023 16:06 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | Disposition to issuerStock Option (Right to Buy) · Derivative | 5,948 | $23.19 Strike: $16.81 | $137,934.12 |
DisclosureSEC source: 0001209191-23-045415 · doc4.xml · derivative · entry 6 Jerel Davis · CIK 0001745958 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,948 shares Expires 2031-06-03 F6 · derivative.exercise_date: This stock option award, which vested in full upon the earlier of the one year anniversary of the grant date or the date of the Issuer's next annual stockholders' meeting, was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes. Read SEC document |
| August 11, 2023 Filed Aug 11, 2023 16:06 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | Disposition to issuerStock Option (Right to Buy) · Derivative | 23,522 | $25.23 Strike: $14.77 | $593,460.06 |
DisclosureSEC source: 0001209191-23-045415 · doc4.xml · derivative · entry 5 Jerel Davis · CIK 0001745958 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 23,522 shares Expires 2030-10-05 F5 · derivative.exercise_date: This stock option award, which provided for ratable vesting in 36 monthly installments beginning on November 6, 2020, became fully vested and was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes. Read SEC document |
| August 11, 2023 Filed Aug 11, 2023 16:06 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | Disposition to issuerCommon Stock | 210,996 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-045415 · doc4.xml · nonDerivative · entry 4 Jerel Davis · CIK 0001745958 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 0 F1 · price: The reported securities were disposed of pursuant to the Merger Agreement (defined in the Remarks below). Upon effectiveness of the Merger (defined in the Remarks below), in exchange for each share of the Issuer's Common Stock, the reporting person received: (i) $40.00 in cash, without interest and less applicable withholding taxes; and (ii) one contractual contingent value right (each, a "CVR"), entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement (the "Contingent Value Rights Agreement") entered into concurrent with completion of the Merger. F4 · ownership.nature: These securities are held of record by Versant Voyageurs I Parallel, L.P. ("Versant I Parallel"). Versant Voyageurs I GP, L.P. ("Versant Voyageurs I GP") is the general partner of Versant I Parallel. Versant Ventures VI GP, L.P. ("Versant Ventures VI GP") is the general partner of Versant Voyageurs I GP. Versant Ventures VI GP-GP, LLC ("Versant Ventures VI GP-GP") is the general partner of Versant Ventures VI GP. Jerel C. Davis is a member of the Issuer's board of directors and is a managing director of Versant Ventures VI GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant I Parallel. Each of Jerel C. Davis, Versant Ventures VI GP-GP, Versant Ventures VI GP, and Versant Voyageurs I GP disclaims beneficial ownership of the shares held by Versant I Parallel, except to the extent of their respective pecuniary interests therein. Read SEC document |
| August 11, 2023 Filed Aug 11, 2023 16:06 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | Disposition to issuerCommon Stock | 719,104 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-045415 · doc4.xml · nonDerivative · entry 3 Jerel Davis · CIK 0001745958 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 0 F1 · price: The reported securities were disposed of pursuant to the Merger Agreement (defined in the Remarks below). Upon effectiveness of the Merger (defined in the Remarks below), in exchange for each share of the Issuer's Common Stock, the reporting person received: (i) $40.00 in cash, without interest and less applicable withholding taxes; and (ii) one contractual contingent value right (each, a "CVR"), entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement (the "Contingent Value Rights Agreement") entered into concurrent with completion of the Merger. F3 · ownership.nature: These securities are held of record by Versant Voyageurs I, L.P. ("Versant Voyageurs I"). Versant Voyageurs I GP Company is the general partner of Versant Voyageurs I. Jerel C. Davis is a member of the Issuer's board of directors and is a director of Versant Voyageurs I GP Company and may be deemed to share voting and dispositive power over the shares held by Versant Voyageurs I. Each of Jerel C. Davis and Versant Voyageurs I GP Company disclaims beneficial ownership of the shares held by Versant Voyageurs I, except to the extent of their respective pecuniary interests therein. Read SEC document |
| August 11, 2023 Filed Aug 11, 2023 16:06 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | Disposition to issuerCommon Stock | 2,105,107 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-045415 · doc4.xml · nonDerivative · entry 2 Jerel Davis · CIK 0001745958 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 0 F1 · price: The reported securities were disposed of pursuant to the Merger Agreement (defined in the Remarks below). Upon effectiveness of the Merger (defined in the Remarks below), in exchange for each share of the Issuer's Common Stock, the reporting person received: (i) $40.00 in cash, without interest and less applicable withholding taxes; and (ii) one contractual contingent value right (each, a "CVR"), entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement (the "Contingent Value Rights Agreement") entered into concurrent with completion of the Merger. F2 · ownership.nature: These securities are held of record by Versant Venture Capital VII, L.P. ("Versant VII"). Versant Ventures VII GP, L.P. ("Versant Ventures VII GP") is the general partner of Versant VII, and Versant Ventures VII GP-GP, LLC ("Versant Ventures VII GP-GP") is the general partner of Versant Ventures VII GP. Jerel C. Davis is a member of the Issuer's board of directors and is a managing director of Versant Ventures VII GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant VII. Each of Jerel C. Davis, Versant Ventures VII GP-GP, and Versant Ventures VII GP disclaims beneficial ownership of the shares held by Versant VII, except to the extent of their respective pecuniary interests therein. Read SEC document |
| August 11, 2023 Filed Aug 11, 2023 16:06 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | Disposition to issuerCommon Stock | 447,013 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-045415 · doc4.xml · nonDerivative · entry 1 Jerel Davis · CIK 0001745958 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: The reported securities were disposed of pursuant to the Merger Agreement (defined in the Remarks below). Upon effectiveness of the Merger (defined in the Remarks below), in exchange for each share of the Issuer's Common Stock, the reporting person received: (i) $40.00 in cash, without interest and less applicable withholding taxes; and (ii) one contractual contingent value right (each, a "CVR"), entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement (the "Contingent Value Rights Agreement") entered into concurrent with completion of the Merger. Read SEC document |
| July 25, 2023 Filed Jul 27, 2023 16:21 UTC | Turnstone Biologics Corp. TSBX · Entity 76646 | ConversionSeries D Preferred Stock · Derivative | 2,196,402 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-043525 · doc4.xml · derivative · entry 26 Jerel Davis · CIK 0001745958 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Versant Vantage II, L.P. Disclosed balance after: 0 Underlying: Common Stock · 274,990 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date. F1 · derivative.exercise_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date. F1 · derivative.expiration_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date. F6 · ownership.nature: Shares held by Versant Vantage II, L.P. ("Vantage II"). Versant Vantage II GP, L.P. ("Vantage II GP") is the sole general partner of Vantage II and Versant Vantage II GP-GP, LLC (Vantage II GP-GP") is the sole general partner of Vantage II GP. The Reporting Person, a member of the Issuer's board of directors, is a managing director of Vantage II GP-GP and may be deemed to share voting and dispositive power over the shares held by Vantage II. The Reporting Person disclaims beneficial ownership of the shares held by Canada V, except to the extent of his respective pecuniary interest therein. Read SEC document |
| July 25, 2023 Filed Jul 27, 2023 16:21 UTC | Turnstone Biologics Corp. TSBX · Entity 76646 | ConversionSeries C Preferred Stock · Derivative | 33,682 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-043525 · doc4.xml · derivative · entry 25 Jerel Davis · CIK 0001745958 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Versant Affiliates Fund V, L.P. Disclosed balance after: 0 Underlying: Common Stock · 4,216 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date. F1 · derivative.exercise_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date. F1 · derivative.expiration_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date. F5 · ownership.nature: Shares are held by Versant Affiliates Fund V, L.P. ("Affiliates V"). Versant V GP is the sole general partner of Affiliates V. The Reporting Person, a member of the Issuer's board of directors, is a managing director of Versant V GP and may be deemed to share voting and dispositive power over the shares held by Affiliates V. The Reporting Person disclaims beneficial ownership of the shares held by Affiliates, except to the extent of his respective pecuniary interest therein. Read SEC document |
| July 25, 2023 Filed Jul 27, 2023 16:21 UTC | Turnstone Biologics Corp. TSBX · Entity 76646 | ConversionSeries C Preferred Stock · Derivative | 37,283 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-043525 · doc4.xml · derivative · entry 24 Jerel Davis · CIK 0001745958 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Versant Ophthalmic Affiliates Fund I, L.P. Disclosed balance after: 0 Underlying: Common Stock · 4,667 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date. F1 · derivative.exercise_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date. F1 · derivative.expiration_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date. F4 · ownership.nature: Shares are held by Versant Ophthalmic Affiliates Fund I, L.P. ("Ophthalmic"). Versant V GP is the sole general partner of Ophthalmic. The Reporting Person, a member of the Issuer's board of directors, is a managing director of Versant V GP and may be deemed to share voting and dispositive power over the shares held by Ophthalmic. The Reporting Person disclaims beneficial ownership of the shares held by Ophthalmic, except to the extent of his respective pecuniary interest therein. Read SEC document |
| July 25, 2023 Filed Jul 27, 2023 16:21 UTC | Turnstone Biologics Corp. TSBX · Entity 76646 | ConversionSeries C Preferred Stock · Derivative | 85,217 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-043525 · doc4.xml · derivative · entry 23 Jerel Davis · CIK 0001745958 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Versant Venture Capital V (Canada) LP Disclosed balance after: 0 Underlying: Common Stock · 10,669 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date. F1 · derivative.exercise_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date. F1 · derivative.expiration_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date. F3 · ownership.nature: Shares are held by Versant Venture Capital V (Canada) LP ("Canada V"). Versant Ventures V (Canada), L.P. ("Canada V GP") is the general partner of Canada V and Versant Ventures V GP-GP (Canada), Inc. ("Canada V GP-GP") is the sole general partner of Canada V GP. The Reporting Person, a member of the Issuer's board of directors, is a director of Canada V GP-GP and may be deemed to share voting and dispositive power over the shares held by Canada V. The Reporting Person disclaims beneficial ownership of the shares held by Canada V, except to the extent of his respective pecuniary interest therein. Read SEC document |
| July 25, 2023 Filed Jul 27, 2023 16:21 UTC | Turnstone Biologics Corp. TSBX · Entity 76646 | ConversionSeries C Preferred Stock · Derivative | 1,119,729 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-043525 · doc4.xml · derivative · entry 22 Jerel Davis · CIK 0001745958 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Versant Venture Capital V, L.P. Disclosed balance after: 0 Underlying: Common Stock · 140,190 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date. F1 · derivative.exercise_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date. F1 · derivative.expiration_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date. F2 · ownership.nature: Shares are held by Versant Venture Capital V, L.P. ("Versant V"). Versant Ventures V, LLC ("Versant V GP") is the sole general partner of Versant V. The Reporting Person, a member of the Issuer's board of directors, is a managing director of Versant V GP and may be deemed to share voting and dispositive power over the shares held by Versant V. The Reporting Persons disclaims beneficial ownership of the shares held by Versant V, except to the extent of his respective pecuniary interest therein. Read SEC document |
| July 25, 2023 Filed Jul 27, 2023 16:21 UTC | Turnstone Biologics Corp. TSBX · Entity 76646 | ConversionSeries B-2 Preferred Stock · Derivative | 230,117 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-043525 · doc4.xml · derivative · entry 21 Jerel Davis · CIK 0001745958 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Versant Affiliates Fund V, L.P. Disclosed balance after: 0 Underlying: Common Stock · 28,810 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date. F1 · derivative.exercise_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date. F1 · derivative.expiration_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date. F5 · ownership.nature: Shares are held by Versant Affiliates Fund V, L.P. ("Affiliates V"). Versant V GP is the sole general partner of Affiliates V. The Reporting Person, a member of the Issuer's board of directors, is a managing director of Versant V GP and may be deemed to share voting and dispositive power over the shares held by Affiliates V. The Reporting Person disclaims beneficial ownership of the shares held by Affiliates, except to the extent of his respective pecuniary interest therein. Read SEC document |
| July 25, 2023 Filed Jul 27, 2023 16:21 UTC | Turnstone Biologics Corp. TSBX · Entity 76646 | ConversionSeries B-2 Preferred Stock · Derivative | 255,081 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-043525 · doc4.xml · derivative · entry 20 Jerel Davis · CIK 0001745958 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Versant Ophthalmic Affiliates Fund I, L.P. Disclosed balance after: 0 Underlying: Common Stock · 31,936 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date. F1 · derivative.exercise_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date. F1 · derivative.expiration_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date. F4 · ownership.nature: Shares are held by Versant Ophthalmic Affiliates Fund I, L.P. ("Ophthalmic"). Versant V GP is the sole general partner of Ophthalmic. The Reporting Person, a member of the Issuer's board of directors, is a managing director of Versant V GP and may be deemed to share voting and dispositive power over the shares held by Ophthalmic. The Reporting Person disclaims beneficial ownership of the shares held by Ophthalmic, except to the extent of his respective pecuniary interest therein. Read SEC document |
| July 25, 2023 Filed Jul 27, 2023 16:21 UTC | Turnstone Biologics Corp. TSBX · Entity 76646 | ConversionSeries B-2 Preferred Stock · Derivative | 582,206 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-043525 · doc4.xml · derivative · entry 19 Jerel Davis · CIK 0001745958 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Versant Venture Capital V (Canada) LP Disclosed balance after: 0 Underlying: Common Stock · 72,892 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date. F1 · derivative.exercise_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date. F1 · derivative.expiration_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date. F3 · ownership.nature: Shares are held by Versant Venture Capital V (Canada) LP ("Canada V"). Versant Ventures V (Canada), L.P. ("Canada V GP") is the general partner of Canada V and Versant Ventures V GP-GP (Canada), Inc. ("Canada V GP-GP") is the sole general partner of Canada V GP. The Reporting Person, a member of the Issuer's board of directors, is a director of Canada V GP-GP and may be deemed to share voting and dispositive power over the shares held by Canada V. The Reporting Person disclaims beneficial ownership of the shares held by Canada V, except to the extent of his respective pecuniary interest therein. Read SEC document |
| July 25, 2023 Filed Jul 27, 2023 16:21 UTC | Turnstone Biologics Corp. TSBX · Entity 76646 | ConversionSeries B-2 Preferred Stock · Derivative | 7,650,043 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-043525 · doc4.xml · derivative · entry 18 Jerel Davis · CIK 0001745958 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Versant Venture Capital V, L.P. Disclosed balance after: 0 Underlying: Common Stock · 957,787 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date. F1 · derivative.exercise_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date. F1 · derivative.expiration_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date. F2 · ownership.nature: Shares are held by Versant Venture Capital V, L.P. ("Versant V"). Versant Ventures V, LLC ("Versant V GP") is the sole general partner of Versant V. The Reporting Person, a member of the Issuer's board of directors, is a managing director of Versant V GP and may be deemed to share voting and dispositive power over the shares held by Versant V. The Reporting Persons disclaims beneficial ownership of the shares held by Versant V, except to the extent of his respective pecuniary interest therein. Read SEC document |
| July 25, 2023 Filed Jul 27, 2023 16:21 UTC | Turnstone Biologics Corp. TSBX · Entity 76646 | ConversionSeries B-1 Preferred Stock · Derivative | 106,208 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-043525 · doc4.xml · derivative · entry 17 Jerel Davis · CIK 0001745958 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Versant Affiliates Fund V, L.P. Disclosed balance after: 0 Underlying: Common Stock · 13,297 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date. F1 · derivative.exercise_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date. F1 · derivative.expiration_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date. F5 · ownership.nature: Shares are held by Versant Affiliates Fund V, L.P. ("Affiliates V"). Versant V GP is the sole general partner of Affiliates V. The Reporting Person, a member of the Issuer's board of directors, is a managing director of Versant V GP and may be deemed to share voting and dispositive power over the shares held by Affiliates V. The Reporting Person disclaims beneficial ownership of the shares held by Affiliates, except to the extent of his respective pecuniary interest therein. Read SEC document |
| July 25, 2023 Filed Jul 27, 2023 16:21 UTC | Turnstone Biologics Corp. TSBX · Entity 76646 | ConversionSeries B-1 Preferred Stock · Derivative | 117,730 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-043525 · doc4.xml · derivative · entry 16 Jerel Davis · CIK 0001745958 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Versant Ophthalmic Affiliates Fund I, L.P. Disclosed balance after: 0 Underlying: Common Stock · 14,739 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date. F1 · derivative.exercise_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date. F1 · derivative.expiration_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date. F4 · ownership.nature: Shares are held by Versant Ophthalmic Affiliates Fund I, L.P. ("Ophthalmic"). Versant V GP is the sole general partner of Ophthalmic. The Reporting Person, a member of the Issuer's board of directors, is a managing director of Versant V GP and may be deemed to share voting and dispositive power over the shares held by Ophthalmic. The Reporting Person disclaims beneficial ownership of the shares held by Ophthalmic, except to the extent of his respective pecuniary interest therein. Read SEC document |
| July 25, 2023 Filed Jul 27, 2023 16:21 UTC | Turnstone Biologics Corp. TSBX · Entity 76646 | ConversionSeries B-1 Preferred Stock · Derivative | 268,711 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-043525 · doc4.xml · derivative · entry 15 Jerel Davis · CIK 0001745958 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Versant Venture Capital V (Canada) LP Disclosed balance after: 0 Underlying: Common Stock · 33,642 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date. F1 · derivative.exercise_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date. F1 · derivative.expiration_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date. F3 · ownership.nature: Shares are held by Versant Venture Capital V (Canada) LP ("Canada V"). Versant Ventures V (Canada), L.P. ("Canada V GP") is the general partner of Canada V and Versant Ventures V GP-GP (Canada), Inc. ("Canada V GP-GP") is the sole general partner of Canada V GP. The Reporting Person, a member of the Issuer's board of directors, is a director of Canada V GP-GP and may be deemed to share voting and dispositive power over the shares held by Canada V. The Reporting Person disclaims beneficial ownership of the shares held by Canada V, except to the extent of his respective pecuniary interest therein. Read SEC document |
| July 25, 2023 Filed Jul 27, 2023 16:21 UTC | Turnstone Biologics Corp. TSBX · Entity 76646 | ConversionSeries B-1 Preferred Stock · Derivative | 3,530,789 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-043525 · doc4.xml · derivative · entry 14 Jerel Davis · CIK 0001745958 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Versant Venture Capital V, L.P. Disclosed balance after: 0 Underlying: Common Stock · 442,055 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date. F1 · derivative.exercise_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date. F1 · derivative.expiration_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date. F2 · ownership.nature: Shares are held by Versant Venture Capital V, L.P. ("Versant V"). Versant Ventures V, LLC ("Versant V GP") is the sole general partner of Versant V. The Reporting Person, a member of the Issuer's board of directors, is a managing director of Versant V GP and may be deemed to share voting and dispositive power over the shares held by Versant V. The Reporting Persons disclaims beneficial ownership of the shares held by Versant V, except to the extent of his respective pecuniary interest therein. Read SEC document |
| July 25, 2023 Filed Jul 27, 2023 16:21 UTC | Turnstone Biologics Corp. TSBX · Entity 76646 | ConversionSeries A Preferred Stock · Derivative | 237,575 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-043525 · doc4.xml · derivative · entry 13 Jerel Davis · CIK 0001745958 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Versant Affiliates Fund V, L.P. Disclosed balance after: 0 Underlying: Common Stock · 29,744 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date. F1 · derivative.exercise_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date. F1 · derivative.expiration_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date. F5 · ownership.nature: Shares are held by Versant Affiliates Fund V, L.P. ("Affiliates V"). Versant V GP is the sole general partner of Affiliates V. The Reporting Person, a member of the Issuer's board of directors, is a managing director of Versant V GP and may be deemed to share voting and dispositive power over the shares held by Affiliates V. The Reporting Person disclaims beneficial ownership of the shares held by Affiliates, except to the extent of his respective pecuniary interest therein. Read SEC document |
| July 25, 2023 Filed Jul 27, 2023 16:21 UTC | Turnstone Biologics Corp. TSBX · Entity 76646 | ConversionSeries A Preferred Stock · Derivative | 263,349 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-043525 · doc4.xml · derivative · entry 12 Jerel Davis · CIK 0001745958 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Versant Ophthalmic Affiliates Fund I, L.P. Disclosed balance after: 0 Underlying: Common Stock · 32,971 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date. F1 · derivative.exercise_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date. F1 · derivative.expiration_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date. F4 · ownership.nature: Shares are held by Versant Ophthalmic Affiliates Fund I, L.P. ("Ophthalmic"). Versant V GP is the sole general partner of Ophthalmic. The Reporting Person, a member of the Issuer's board of directors, is a managing director of Versant V GP and may be deemed to share voting and dispositive power over the shares held by Ophthalmic. The Reporting Person disclaims beneficial ownership of the shares held by Ophthalmic, except to the extent of his respective pecuniary interest therein. Read SEC document |
| July 25, 2023 Filed Jul 27, 2023 16:21 UTC | Turnstone Biologics Corp. TSBX · Entity 76646 | ConversionSeries A Preferred Stock · Derivative | 601,077 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-043525 · doc4.xml · derivative · entry 11 Jerel Davis · CIK 0001745958 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Versant Venture Capital V (Canada) LP Disclosed balance after: 0 Underlying: Common Stock · 75,255 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date. F1 · derivative.exercise_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date. F1 · derivative.expiration_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date. F3 · ownership.nature: Shares are held by Versant Venture Capital V (Canada) LP ("Canada V"). Versant Ventures V (Canada), L.P. ("Canada V GP") is the general partner of Canada V and Versant Ventures V GP-GP (Canada), Inc. ("Canada V GP-GP") is the sole general partner of Canada V GP. The Reporting Person, a member of the Issuer's board of directors, is a director of Canada V GP-GP and may be deemed to share voting and dispositive power over the shares held by Canada V. The Reporting Person disclaims beneficial ownership of the shares held by Canada V, except to the extent of his respective pecuniary interest therein. Read SEC document |
| July 25, 2023 Filed Jul 27, 2023 16:21 UTC | Turnstone Biologics Corp. TSBX · Entity 76646 | ConversionSeries A Preferred Stock · Derivative | 7,897,999 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-043525 · doc4.xml · derivative · entry 10 Jerel Davis · CIK 0001745958 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Versant Venture Capital V, L.P. Disclosed balance after: 0 Underlying: Common Stock · 988,832 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date. F1 · derivative.exercise_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date. F1 · derivative.expiration_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date. F2 · ownership.nature: Shares are held by Versant Venture Capital V, L.P. ("Versant V"). Versant Ventures V, LLC ("Versant V GP") is the sole general partner of Versant V. The Reporting Person, a member of the Issuer's board of directors, is a managing director of Versant V GP and may be deemed to share voting and dispositive power over the shares held by Versant V. The Reporting Persons disclaims beneficial ownership of the shares held by Versant V, except to the extent of his respective pecuniary interest therein. Read SEC document |
| July 25, 2023 Filed Jul 27, 2023 16:21 UTC | Turnstone Biologics Corp. TSBX · Entity 76646 | PurchaseCommon Stock | 5,939 | $12.00 | $71,268.00 |
DisclosureSEC source: 0001209191-23-043525 · doc4.xml · nonDerivative · entry 9 Jerel Davis · CIK 0001745958 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Versant Affiliates Fund V, L.P. Disclosed balance after: 82,006 F5 · ownership.nature: Shares are held by Versant Affiliates Fund V, L.P. ("Affiliates V"). Versant V GP is the sole general partner of Affiliates V. The Reporting Person, a member of the Issuer's board of directors, is a managing director of Versant V GP and may be deemed to share voting and dispositive power over the shares held by Affiliates V. The Reporting Person disclaims beneficial ownership of the shares held by Affiliates, except to the extent of his respective pecuniary interest therein. Read SEC document |
| July 25, 2023 Filed Jul 27, 2023 16:21 UTC | Turnstone Biologics Corp. TSBX · Entity 76646 | PurchaseCommon Stock | 6,575 | $12.00 | $78,900.00 |
DisclosureSEC source: 0001209191-23-043525 · doc4.xml · nonDerivative · entry 8 Jerel Davis · CIK 0001745958 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Versant Ophthalmic Affiliates Fund I, L.P. Disclosed balance after: 90,888 F4 · ownership.nature: Shares are held by Versant Ophthalmic Affiliates Fund I, L.P. ("Ophthalmic"). Versant V GP is the sole general partner of Ophthalmic. The Reporting Person, a member of the Issuer's board of directors, is a managing director of Versant V GP and may be deemed to share voting and dispositive power over the shares held by Ophthalmic. The Reporting Person disclaims beneficial ownership of the shares held by Ophthalmic, except to the extent of his respective pecuniary interest therein. Read SEC document |
| July 25, 2023 Filed Jul 27, 2023 16:21 UTC | Turnstone Biologics Corp. TSBX · Entity 76646 | PurchaseCommon Stock | 15,028 | $12.00 | $180,336.00 |
DisclosureSEC source: 0001209191-23-043525 · doc4.xml · nonDerivative · entry 7 Jerel Davis · CIK 0001745958 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Versant Venture Capital V (Canada) LP Disclosed balance after: 207,486 F3 · ownership.nature: Shares are held by Versant Venture Capital V (Canada) LP ("Canada V"). Versant Ventures V (Canada), L.P. ("Canada V GP") is the general partner of Canada V and Versant Ventures V GP-GP (Canada), Inc. ("Canada V GP-GP") is the sole general partner of Canada V GP. The Reporting Person, a member of the Issuer's board of directors, is a director of Canada V GP-GP and may be deemed to share voting and dispositive power over the shares held by Canada V. The Reporting Person disclaims beneficial ownership of the shares held by Canada V, except to the extent of his respective pecuniary interest therein. Read SEC document |
| July 25, 2023 Filed Jul 27, 2023 16:21 UTC | Turnstone Biologics Corp. TSBX · Entity 76646 | PurchaseCommon Stock | 197,458 | $12.00 | $2,369,496.00 |
DisclosureSEC source: 0001209191-23-043525 · doc4.xml · nonDerivative · entry 6 Jerel Davis · CIK 0001745958 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Versant Venture Capital V, L.P. Disclosed balance after: 2,726,322 F2 · ownership.nature: Shares are held by Versant Venture Capital V, L.P. ("Versant V"). Versant Ventures V, LLC ("Versant V GP") is the sole general partner of Versant V. The Reporting Person, a member of the Issuer's board of directors, is a managing director of Versant V GP and may be deemed to share voting and dispositive power over the shares held by Versant V. The Reporting Persons disclaims beneficial ownership of the shares held by Versant V, except to the extent of his respective pecuniary interest therein. Read SEC document |
| July 25, 2023 Filed Jul 27, 2023 16:21 UTC | Turnstone Biologics Corp. TSBX · Entity 76646 | ConversionCommon Stock | 274,990 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-043525 · doc4.xml · nonDerivative · entry 5 Jerel Davis · CIK 0001745958 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Versant Vantage II, L.P. Disclosed balance after: 274,990 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date. F6 · ownership.nature: Shares held by Versant Vantage II, L.P. ("Vantage II"). Versant Vantage II GP, L.P. ("Vantage II GP") is the sole general partner of Vantage II and Versant Vantage II GP-GP, LLC (Vantage II GP-GP") is the sole general partner of Vantage II GP. The Reporting Person, a member of the Issuer's board of directors, is a managing director of Vantage II GP-GP and may be deemed to share voting and dispositive power over the shares held by Vantage II. The Reporting Person disclaims beneficial ownership of the shares held by Canada V, except to the extent of his respective pecuniary interest therein. Read SEC document |
| July 25, 2023 Filed Jul 27, 2023 16:21 UTC | Turnstone Biologics Corp. TSBX · Entity 76646 | ConversionCommon Stock | 76,067 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-043525 · doc4.xml · nonDerivative · entry 4 Jerel Davis · CIK 0001745958 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Versant Affiliates Fund V, L.P. Disclosed balance after: 76,067 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date. F5 · ownership.nature: Shares are held by Versant Affiliates Fund V, L.P. ("Affiliates V"). Versant V GP is the sole general partner of Affiliates V. The Reporting Person, a member of the Issuer's board of directors, is a managing director of Versant V GP and may be deemed to share voting and dispositive power over the shares held by Affiliates V. The Reporting Person disclaims beneficial ownership of the shares held by Affiliates, except to the extent of his respective pecuniary interest therein. Read SEC document |
| July 25, 2023 Filed Jul 27, 2023 16:21 UTC | Turnstone Biologics Corp. TSBX · Entity 76646 | ConversionCommon Stock | 84,313 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-043525 · doc4.xml · nonDerivative · entry 3 Jerel Davis · CIK 0001745958 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Versant Ophthalmic Affiliates Fund I, L.P. Disclosed balance after: 84,313 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date. F4 · ownership.nature: Shares are held by Versant Ophthalmic Affiliates Fund I, L.P. ("Ophthalmic"). Versant V GP is the sole general partner of Ophthalmic. The Reporting Person, a member of the Issuer's board of directors, is a managing director of Versant V GP and may be deemed to share voting and dispositive power over the shares held by Ophthalmic. The Reporting Person disclaims beneficial ownership of the shares held by Ophthalmic, except to the extent of his respective pecuniary interest therein. Read SEC document |
| July 25, 2023 Filed Jul 27, 2023 16:21 UTC | Turnstone Biologics Corp. TSBX · Entity 76646 | ConversionCommon Stock | 192,458 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-043525 · doc4.xml · nonDerivative · entry 2 Jerel Davis · CIK 0001745958 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Versant Venture Capital V (Canada) LP Disclosed balance after: 192,458 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date. F3 · ownership.nature: Shares are held by Versant Venture Capital V (Canada) LP ("Canada V"). Versant Ventures V (Canada), L.P. ("Canada V GP") is the general partner of Canada V and Versant Ventures V GP-GP (Canada), Inc. ("Canada V GP-GP") is the sole general partner of Canada V GP. The Reporting Person, a member of the Issuer's board of directors, is a director of Canada V GP-GP and may be deemed to share voting and dispositive power over the shares held by Canada V. The Reporting Person disclaims beneficial ownership of the shares held by Canada V, except to the extent of his respective pecuniary interest therein. Read SEC document |
| July 25, 2023 Filed Jul 27, 2023 16:21 UTC | Turnstone Biologics Corp. TSBX · Entity 76646 | ConversionCommon Stock | 2,528,864 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-043525 · doc4.xml · nonDerivative · entry 1 Jerel Davis · CIK 0001745958 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Versant Venture Capital V, L.P. Disclosed balance after: 2,528,864 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date. F2 · ownership.nature: Shares are held by Versant Venture Capital V, L.P. ("Versant V"). Versant Ventures V, LLC ("Versant V GP") is the sole general partner of Versant V. The Reporting Person, a member of the Issuer's board of directors, is a managing director of Versant V GP and may be deemed to share voting and dispositive power over the shares held by Versant V. The Reporting Persons disclaims beneficial ownership of the shares held by Versant V, except to the extent of his respective pecuniary interest therein. Read SEC document |
| July 19, 2023 Filed Jul 21, 2023 21:07 UTC | LENZ Therapeutics, Inc. GRPH · Entity 6475 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $2.72 | $0.00 |
DisclosureSEC source: 0001209191-23-043134 · doc4.xml · derivative · entry 1 Jerel Davis · CIK 0001745958 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2033-07-18 F1 · derivative.exercise_date: The shares subject to such option vest in full on the earlier of (i) the one-year anniversary of the grant date or on (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service as a director as of the applicable vesting date. Read SEC document |
| May 26, 2023 Filed May 31, 2023 19:22 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | Exercise / conversionRestricted Stock Units · Derivative | 3,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-033187 · doc4.xml · derivative · entry 2 Jerel Davis · CIK 0001745958 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,300 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer's common stock. F3 · derivative.exercise_date: 100% of the RSUs vested on May 26, 2023, subject to the Reporting Persons continued service to the Issuer on the vesting date. F3 · derivative.expiration_date: 100% of the RSUs vested on May 26, 2023, subject to the Reporting Persons continued service to the Issuer on the vesting date. Read SEC document |
| May 26, 2023 Filed May 31, 2023 19:22 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | Exercise / conversionCommon Stock | 3,300 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-033187 · doc4.xml · nonDerivative · entry 1 Jerel Davis · CIK 0001745958 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 733,770 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. Read SEC document |
| April 17, 2023 Filed Apr 19, 2023 17:58 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | SaleCommon Stock | 295,808 | $20.75 | $6,138,223.07 |
DisclosureSEC source: 0000899243-23-011458 · doc4.xml · nonDerivative · entry 1 Jerel Davis · CIK 0001745958 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 443,713 F1 · kind: Pursuant to an arrangement between the Reporting Person and Versant Venture Management, LLC ("VVM"), the sale of these securities was executed by VVM on behalf of the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $20.75 to $20.97, inclusive. The Reporting Person and VVM undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 16:13 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | SaleCommon Stock | 36,751 | $22.75 | $836,085.25 |
DisclosureSEC source: 0000899243-23-006968 · doc4.xml · nonDerivative · entry 3 Jerel Davis · CIK 0001745958 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 210,996 F3 · ownership.nature: These securities are held of record by Versant Voyageurs I Parallel, L.P. ("Versant I Parallel"). Versant Voyageurs I GP, L.P. ("Versant Voyageurs I GP") is the general partner of Versant I Parallel. Versant Ventures VI GP, L.P. ("Versant Ventures VI GP") is the general partner of Versant Voyageurs I GP. Versant Ventures VI GP-GP, LLC ("Versant Ventures VI GP-GP") is the general partner of Versant Ventures VI GP. The Reporting Person, a member of the Issuer's board of directors, is a managing director of Versant Ventures VI GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant I Parallel. Each of Versant Ventures VI GP-GP, Versant Ventures VI GP, Versant Voyageurs I GP and the Reporting Person disclaims beneficial ownership of the shares held by Versant I Parallel, except to the extent of their respective pecuniary interests therein. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 16:13 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | SaleCommon Stock | 123,249 | $22.75 | $2,803,914.75 |
DisclosureSEC source: 0000899243-23-006968 · doc4.xml · nonDerivative · entry 2 Jerel Davis · CIK 0001745958 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 719,104 F2 · ownership.nature: These securities are held of record by Versant Voyageurs I, L.P. ("Versant Voyageurs I"). Versant Voyageurs I GP Company is the general partner of Versant Voyageurs I. The Reporting Person, a member of the Issuer's board of directors, is a director of Versant Voyageurs I GP Company and may be deemed to share voting and dispositive power over the shares held by Versant Voyageurs I. Each of Versant Voyageurs I GP Company and the Reporting Person disclaims beneficial ownership of the shares held by Versant Voyageurs I, except to the extent of their respective pecuniary interests therein. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 16:13 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | SaleCommon Stock | 240,000 | $22.75 | $5,460,000.00 |
DisclosureSEC source: 0000899243-23-006968 · doc4.xml · nonDerivative · entry 1 Jerel Davis · CIK 0001745958 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,105,107 F1 · ownership.nature: These securities are held of record by Versant Venture Capital VII, L.P. ("Versant VII"). Versant Ventures VII GP, L.P. ("Versant Ventures VII GP") is the general partner of Versant VII, and Versant Ventures VII GP-GP, LLC ("Versant Ventures VII GP-GP") is the general partner of Versant Ventures VII GP. The Reporting Person, a member of the Issuer's board of directors, is a managing director of Versant Ventures VII GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant VII. Each of Versant Ventures VII GP-GP, Versant Ventures VII GP and the Reporting Person disclaims beneficial ownership of the shares held by Versant VII, except to the extent of their respective pecuniary interests therein. Read SEC document |
| December 29, 2022 Filed Jan 3, 2023 21:38 UTC | Repare Therapeutics Inc. RPTX · Entity 68433 | OtherCommon Shares | 3,014 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-000260 · doc4.xml · nonDerivative · entry 12 Jerel Davis · CIK 0001745958 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,131 F18 · kind: Represents a change in the form of ownership of the Reporting Person by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VV V (Canada). Read SEC document |
| December 29, 2022 Filed Jan 3, 2023 21:38 UTC | Repare Therapeutics Inc. RPTX · Entity 68433 | OtherCommon Shares | 4,721 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-000260 · doc4.xml · nonDerivative · entry 11 Jerel Davis · CIK 0001745958 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 F17 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by VV V (Canada), to its partners. F16 · ownership.nature: Shares held by VV V (Canada). VV V (Canada) GP is the sole general partner of VV V (Canada). The Reporting Person, a member of the Issuer's board of directors, is a director of VV V (Canada) GP and may be deemed to share voting and dispositive power over the shares held by VV V (Canada). Each of VV V (Canada) GP and the Reporting Person disclaims beneficial ownership of the shares held by VV V (Canada), except to the extent of their respective pecuniary interests therein. Read SEC document |
| December 29, 2022 Filed Jan 3, 2023 21:38 UTC | Repare Therapeutics Inc. RPTX · Entity 68433 | OtherCommon Shares | 4,721 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-000260 · doc4.xml · nonDerivative · entry 10 Jerel Davis · CIK 0001745958 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 4,721 F15 · kind: Represents a change in the form of ownership of VV V (Canada) by virtue of the receipt of shares in the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VVC V (Canada). F16 · ownership.nature: Shares held by VV V (Canada). VV V (Canada) GP is the sole general partner of VV V (Canada). The Reporting Person, a member of the Issuer's board of directors, is a director of VV V (Canada) GP and may be deemed to share voting and dispositive power over the shares held by VV V (Canada). Each of VV V (Canada) GP and the Reporting Person disclaims beneficial ownership of the shares held by VV V (Canada), except to the extent of their respective pecuniary interests therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.